Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLuOrescence to Identify the Thoracic Duct (FLOTOR)
NCT03292757Phase 2Completed
- Sponsor
- Oxford University Hospitals
- Start
- Dec 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of indocyanine green in esophageal cancer (2 arms), sponsored by Oxford University Hospitals. Primary endpoint: Number of thoracic ducts seen under fluorescence versus number of thoracic ducts seen with white light. Started Dec 2017; status: completed.
02
Drugs
indocyanine green
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03292757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292757.